AssetMark’s Tonix Pharmaceuticals TNXP Stock Holding History
Bought
Maintained
Sold
Other funds holding TNXP
JHC
AssetMark's TNXP Position: Q3 2026 in Review
AssetMark held its Tonix Pharmaceuticals (TNXP) position steady in Q3 2026 at 3 shares worth $29. The position accounts for ﹤0.01% of the portfolio, ranked #3739.
AssetMark first reported a position in TNXP in Q1 2025 and has held it in 7 quarters since. The position peaked at $108 in Q2 2025. 76 funds tracked by Wall St. Rank hold TNXP as of Q3 2026.
- AssetMark held 3 shares of Tonix Pharmaceuticals worth $29 as of Q3 2026.
- AssetMark left its Tonix Pharmaceuticals share count unchanged in Q3 2026.
- Tonix Pharmaceuticals made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3739 holding.
- AssetMark first reported a position in Tonix Pharmaceuticals in Q1 2025 and has held it in 7 quarters since.
- AssetMark's Tonix Pharmaceuticals position peaked at $108 in Q2 2025.
- 76 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.